FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the pharmaceutical industry and includes a pharmaceutical composition, representing a solution of a triindolylmethane derivative - a pharmaceutically acceptable salt of tris(1-pentyl-1H-indol-3-yl)methylium, in particular tris(1-pentyl-1H-indol-3-yl)methylium chloride, in a pharmaceutically acceptable polysorbate (tween), in particular polysorbate-80 (tween-80).
EFFECT: composition is applied for the therapy of human or animal malignant tumours.
4 tbl, 3 ex
Title | Year | Author | Number |
---|---|---|---|
APPLICATION OF TRIINDOLYL METHANE DERIVATIVES AS ANTICANCER DRUGS | 2010 |
|
RU2454232C2 |
PHARMACEUTICAL COMPOSITION BASED ON 6-[(4-METHYL-1-1-PIPERAZINYL)METHYL]-INDOLO[1',7':1,2,3]PYRROLO[3',4':6,7]AZEPINO[4,5-b]INDOLE-1,3(2H,10 H)-DIONE AS ANTI-TUMOUR MEDICATION | 2013 |
|
RU2523387C1 |
N,N'((ALKANDIYL)BIS[LABDA-7(9),13,14-TRIENE-4-CARBOXAMIDES] WITH ANTITUMOUR ACTIVITY | 2017 |
|
RU2654201C1 |
COMBINED DRUG FOR TREATMENT OF TUMOR DISEASES | 2002 |
|
RU2291710C2 |
PREPARATION FOR SELECTIVE APOPTOTIC ELIMINATION OF TUMOUR CELLS | 2014 |
|
RU2567670C2 |
ANTI-TUMOUR PREPARATION | 2014 |
|
RU2569729C1 |
2-AMINOCHROMEN DERIVATIVES EXHIBITING ANTI-TUMOR ACTIVITY; PHARMACEUTICAL COMPOSITIONS | 2018 |
|
RU2704262C1 |
ONCOGENIC RAS-SPECIFIC CYTOTOXIC COMPOUND AND METHODS FOR USING IT | 2006 |
|
RU2448703C2 |
QUINAZOLINE DERIVATIVES INDUCING FERROPTOSIS IN METASTATIC MELANOMA CELLS AND COLON CANCER | 2019 |
|
RU2722308C1 |
BIOLOGICAL MATERIALS AND APPLICATION THEREOF | 2006 |
|
RU2432363C9 |
Authors
Dates
2015-04-27—Published
2012-11-16—Filed